Answers are grounded in this paper and cite their sources.
Durable and balanced immune responses are critical for effectual SARS-CoV-2 vaccination. We compared the immunogenicity of a novel linear doggybone DNA vaccine encoding the full length membrane anchored spike protein of SARS-CoV-2 spike protein (S-dbDNA) with that of a licensed inactivated whole-virion vaccine, Covaxin, in a murine model. S-dbDNA induced significantly higher anti-S1 IgG titres with strong reactivity to the RBD (receptor-binding domain) and superior neutralization of virulent SARS-CoV-2. S-dbDNA also elicited higher frequencies of mono- and polyfunctional CD4 + and CD8 + T cells, along with cytokine-producing NK and NKT cells, compared with Covaxin. Importantly, S-dbDNA generated more durable immune memory, with sustained antibody, neutralization, and T-cell responses detectable up to 120 days post-immunization. These findings support linear DNA vaccines as a promising platform for SARS-CoV-2 and emerging pathogens.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: